GSK1349572
|
|
|
- CAS-Nr.
- 1051375-16-6
- Englisch Name:
- GSK1349572
- Synonyma:
- Dolutegravir;Dolutegravi;S/GSK1349572;Dulutegravir;Dolutegravir (GSK1349572);CS-9;134413;S-349572;GSK1349572;BNKY001-DL04
- CBNumber:
- CB62538916
- Summenformel:
- C20H19F2N3O5
- Molgewicht:
- 419.38
- MOL-Datei:
- 1051375-16-6.mol
|
GSK1349572 Eigenschaften
- Schmelzpunkt:
- 187-189°C
- Siedepunkt:
- 669.0±55.0 °C(Predicted)
- Dichte
- 1.53
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated, Sonicated)
- pka
- 4.50±1.00(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Pale Beige
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
GSK1349572 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In August 2013, the US FDA approved dolutegravir (also referred to as S/GSK1349572) for the treatment of HIV-1 infection in adults and children ages 12 years and older in combination with other antiretroviral drugs. Dolutegravir was approved in Canada in November 2013. HIV/AIDS remains a global epidemic with 35 million people infected, including 2.3 million new infections as of 2012. Dolutegravir joins raltegravir and elvitegravir (this chapter of ARMC) as the latest of three FDA-approved HIV integrase strand transfer inhibitors (INSTIs). Dolutegravir was discovered by rational design from a literature diketo acid HIV integrase inhibitor utilizing X-ray coordinates to predict ideal bond angles between the diketone and distal benzyl group. In dolutegravir, the monocyclic component of the reported inhibitor was replaced with the tricyclic carbamoyl pyridone moiety. The researchers postulated that the appropriate arrangement of three oxygens would permit chelation with two magnesium ions in the binding site thus affording improved potency. Ultimately, this arrangement along with further modifications afforded dolutegravir, a potent inhibitor of HIV integrase (IC
50=1.7 nM).
Chemische Eigenschaften
White Solid
Definition
ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]ox
zine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1.
GSK1349572 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
GSK1349572 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 335)Lieferanten
1051375-16-6()Verwandte Suche:
- Dolutegravir API
- 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide Dolutegravir (GSK1349572)
- GSK1349572, S-349572, GSK572
- (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- Dolutegravir, >=98%
- Dolutegravir free acid
- GSK1349572
- (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- S/GSK1349572 (GSK1349572)
- GSK1349572(dolutegravir)
- dolutegravir/GSK1349572/S-349572
- Dolutegravir (S/GSK1349572
- CS-9
- Dolutegravir - GSK 1349572 | Soltegravir | Tivicay
- BNKY001-DL04
- S/GSK1349572 (Dolutegravir)
- 134413
- Dolutegravir DTG
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
- Pharmaceutical ingredient against HIV GSK1349572
- GSK1349572 USP/EP/BP
- Dolutegravir (0.1 mg/mL in Methanol)
- Dolutegravir D3Q: What is
Dolutegravir D3 Q: What is the CAS Number of
Dolutegravir D3 Q: What is the storage condition of
Dolutegravir D3 Q: What are the applications of
Dolutegravir D3
- DolutegravirQ: What is
Dolutegravir Q: What is the CAS Number of
Dolutegravir Q: What is the storage condition of
Dolutegravir Q: What are the applications of
Dolutegravir
- Dolutegravir Tablet
- Dolutegravir (GSK1349572)
- Dolutegravi
- Dolutegravir
- S/GSK1349572
- Dulutegravir
- The degree of root wei
- Dolutegravir,HIV Integrase,HIV,inhibit,Human immunodeficiency virus,Inhibitor
- (4R, 12aS) - N - [(2,4-difluorophenyl) methyl] -3,4,6,8,12,12a - hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyridino [1 ', 2': 4,5] pyrazino [2,1-b] [1,3] oxazin-9-formamide
- Dolutegravir Impurity L
- Dolutegravir Impurity 40
- S-349572
- Dotiravir Impurity 1
- (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
- 1051375-16-6
- 10513375-16-6
- 134678-17-8
- C20H19F2N3O5
- API
- Inhibitors
- HIV-1 integrase inhibitor
- Inhibitor
- CMLLYL
- 1051375-16-6
